相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
Bevacizumab: current updates in treatment
Margaret E. M. Van Meter et al.
CURRENT OPINION IN ONCOLOGY (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues
Sandrine Dufort et al.
ANALYTICAL BIOCHEMISTRY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Chemotherapy, which drugs and when
Miriam Koopman et al.
EUROPEAN JOURNAL OF CANCER (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
Cathy Eng
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Setting future standards for KRAS testing in colorectal cancer
H. van Krieken et al.
PHARMACOGENOMICS (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
EGFR and colon cancer: a clinical view
Javier de Castro-Carpeno et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma
Yutaka Suehiro et al.
CLINICAL CANCER RESEARCH (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PIK3CA mutation in colorectal cancer:: Relationship with genetic and epigenetic alterations
Katsuhiko Nosho et al.
NEOPLASIA (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
Shunsuke Kato et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12
Maria Virtudes Cespedes et al.
CARCINOGENESIS (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Microsatellite instability in colorectal cancer
K Söreide et al.
BRITISH JOURNAL OF SURGERY (2006)
Oncogenic PI3K deregulates transcription and translation
AG Bader et al.
NATURE REVIEWS CANCER (2005)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
Mutation analysis of p53, k-ras, and BRAF genes in colorectal cancer progression
D Calistri et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Sensitive Sequencing method for KRAS mutation detection by pyrosequencing
S Ogino et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
The prevalence of PIK3CA mutations in gastric and colon cancer
S Velho et al.
EUROPEAN JOURNAL OF CANCER (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer
G Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma
K Tsukuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma:: influence of tumour site, stage, adjuvant chemotherapy and type of mutation
R Soong et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
